ResultsIQ

ResultsIQ › Latest results › Indegene Limited

Indegene Limited special call summary

NSE: INDGN · BSE: 544172

Special call of 6 Oct 2025, summarised by AI from the filing.

Indegene acquires BioPharm for US $104 million, expects 27-28% EBITDA margin in around six quarters.

Key takeaways

  1. Acquisition Indegene acquired BioPharm for US $104 million on debt-free, cash-free basis plus ~$2 million for excess cash and working capital; deal closed 1 October 2025.
  2. Guidance 27% to 28% EBITDA on net revenue expected in around six quarters; EPS accretive beyond first five to six quarters.
  3. Change BioPharm adds brand-side capabilities and expands HCP data sets from 1.8 million to 3 million.
  4. Driver Cross-selling opportunities within combined customer base and cost synergies from data purchase consolidation and offshoring.
  5. Risk BioPharm top 20 customers are about 80% of revenue, top 10 about 60%.

Original filing on BSE

Indegene Limited Q1 FY27 results

As filed: Revenue ₹1,063 cr (+40% year on year), EBITDA ₹174 cr (+12% year on year), PAT ₹116 cr (0% year on year), EBITDA margin 16.4% (−411 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,003 cr (+33% year on year), EBITDA ₹164 cr (+11% year on year), PAT ₹79.7 cr (−16% year on year), EBITDA margin 16.3% (−314 bps). Score 41 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit before exceptional items growth was well below it. EBITDA margin fell 314 bps year on year. Consolidated profit -32% but standalone +34%. Profit fell 7% from last quarter. Revenue rose ₹247 cr on a year ago, more than the ₹83.0 cr it added the year before. Share price after the results: +5.3% in 30 days (Nifty 500: −0.9%).
  • Q3 FY26: Revenue ₹942 cr (+31% year on year), EBITDA ₹160 cr (+22% year on year), PAT ₹103 cr (−6% year on year), EBITDA margin 16.9% (−126 bps). Score 56 of 100, In line with trend. EBITDA margin fell 126 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +5.7% in 29 days (Nifty 500: +0.1%).
  • Q2 FY26: Revenue ₹804 cr (+17% year on year), EBITDA ₹140 cr (+11% year on year), PAT ₹102 cr (+11% year on year), EBITDA margin 17.4% (−93 bps). Score 51 of 100, In line with trend. EBITDA margin fell 93 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 12% from last quarter. Share price after the results: −3.8% in 29 days (Nifty 500: +0.4%).
  • Q1 FY26: Revenue ₹761 cr (+12% year on year), EBITDA ₹156 cr (+21% year on year), PAT ₹116 cr (+32% year on year), EBITDA margin 20.5% (+144 bps). Score 65 of 100, Above trend. EBITDA margin rose 144 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −0.1% in 29 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹756 cr (+12% year on year), EBITDA ₹147 cr (+5% year on year), PAT ₹118 cr (+24% year on year), EBITDA margin 19.4% (−136 bps). Score 49 of 100, In line with trend. EBITDA margin fell 136 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +2.8% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹720 cr, EBITDA ₹131 cr, PAT ₹110 cr, EBITDA margin 18.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹720 cr). Scored once a year-earlier consolidated quarter exists.
  • Q2 FY25: Revenue ₹687 cr, EBITDA ₹126 cr, PAT ₹92.0 cr, EBITDA margin 18.3%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹687 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Indegene Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.